Details of Disease

General Information of Disease (ID: DISF0NF1)

Disease Name	Keratosis
Synonyms	keratoderma
Disease Class	ED56: Keratosis pilaris
Definition	A skin disorder consisting of hypertrophy of the stratum corneum of the skin.
Disease Hierarchy	DISD4UB1: Keratinization disease DIS9YPUQ: Dermatological disease DISF0NF1: Keratosis
ICD Code	ICD-11 ICD-11: ED56 ICD-10 ICD-10: L57.0
Disease Identifiers	MONDO ID MONDO_0006566 MESH ID D007642 UMLS CUI C0022593 MedGen ID 9625 SNOMED CT ID 254666005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Etretinate	DM2CZFA	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LAS-41007	DMZLM0H	Phase 3	NA	[2]
DAC-060	DMACTBM	Phase 2	NA	[3]
GBL-310	DM2IFJQ	Phase 2	NA	[4]
Limtop	DM05VHW	Phase 2	NA	[5]
Sotirimod	DM5WGUR	Phase 2	Small molecular drug	[6]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MV-9411	DMKXMZZ	Discontinued in Phase 2	NA	[7]
Fosfluridine tidoxil	DMSYLIF	Terminated	Small molecular drug	[8]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACR-125	DMU89QJ	Investigative	NA	[9]
MQX-3016	DMD7JOE	Investigative	NA	[9]
Poly IC-poly arginine	DMXA4HY	Investigative	Vaccine	[10]
Poly-ICR	DMUMJ7B	Investigative	NA	[10]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CAT	TTPS279	Strong	Biomarker	[11]
KEAP1	TT3Z6Y9	Strong	Biomarker	[12]
KRT6A	TT2FX8W	Strong	Genetic Variation	[13]
MPO	TTVCZPI	Strong	Biomarker	[11]
NFE2L2	TTA6ZN2	Strong	Biomarker	[12]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLDN11	OTNN6UTL	Limited	Biomarker	[14]
POMP	OTMPM1P5	Strong	Genetic Variation	[15]
SPTLC1	OTN0Z98K	Strong	Genetic Variation	[16]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7599).
2	ClinicalTrials.gov (NCT01265602) Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis. U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031213)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025788)
5	ClinicalTrials.gov (NCT01611480) Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head. U.S. National Institutes of Health.
6	Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007 May;13(5):552-9.
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015969)
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019549)
9	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753).
11	Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett. 2003 Nov 10;201(1):57-65. doi: 10.1016/s0304-3835(03)00471-3.
12	Genetic analysis of cytoprotective functions supported by graded expression of Keap1.Mol Cell Biol. 2010 Jun;30(12):3016-26. doi: 10.1128/MCB.01591-09. Epub 2010 Apr 19.
13	Pachyonychia Congenita: A Spectrum of KRT6a Mutations in Australian Patients.Pediatr Dermatol. 2016 May;33(3):337-42. doi: 10.1111/pde.12841. Epub 2016 Apr 4.
14	Expression of claudin-11 by tumor cells in cutaneous squamous cell carcinoma is dependent on the activity of p38.Exp Dermatol. 2017 Sep;26(9):771-777. doi: 10.1111/exd.13278. Epub 2017 Apr 10.
15	siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis.PLoS One. 2012;7(1):e29471. doi: 10.1371/journal.pone.0029471. Epub 2012 Jan 3.
16	Exclusion of serine palmitoyltransferase long chain base subunit 2 (SPTLC2) as a common cause for hereditary sensory neuropathy.Neuromuscul Disord. 2002 Oct;12(7-8):656-8. doi: 10.1016/s0960-8966(02)00015-9.